Ratings HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:04 2024-05-08 am EDT			5-day change	1st Jan Change
313 ^GBX	+1.62%		+4.33%	+10.60%

10:30am	HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024	CI
Apr. 26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT

Strengths

The company is in a robust financial situation considering its net cash and margin position.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's enterprise value to sales, at 3.57 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HUTCHMED (CHINA) LIMITED	+10.60%	3.3B	C+
ELI LILLY AND COMPANY	+32.85%	700B	C+
JOHNSON & JOHNSON	-4.81%	358B	C+
MERCK & CO., INC.	+19.10%	330B	B-
ABBVIE INC.	+3.42%	287B	C+
ASTRAZENECA PLC	+15.70%	236B	B+
NOVARTIS AG	+6.68%	202B	B-
ROCHE HOLDING AG	-9.08%	197B	A+
AMGEN INC.	+5.14%	161B	C+
PFIZER, INC.	-2.03%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes